Invoking The Relative: A New Perspective on Family Lore in Stigmatized Communities

Author(s):  
Sheila Bock ◽  
Kate Parker Horigan

In chapter 3, “Invoking the Relative: A New Perspective on Family Lore in Stigmatized Communities,” Sheila Bock and Kate Parker Horigan further extend this volume’s section on disability, ethnography, and the stigmatized vernacular into the narrative and familial realms. While family stories always signify the values and identities of particular groups, they also open up opportunities for individuals to contest articulations of morality and blame in contexts of stigma. Accordingly, Bock and Horigan approach the concept of “family” not only as a classification of a particular folk group or a descriptor of narratives’ thematic content, but as a rhetorical strategy employed by narrators in contexts wherein their reputations and identities are threatened. Bringing together fieldwork materials from two independent studies—one examining accounts of personal and community experiences with Type 2 diabetes and another examining personal narratives of Hurricane Katrina survivors—the authors highlight how the concept of “family” serves as a rich rhetorical resource in individual accounts of community trauma by indexing material and symbolic relationships across both time and space.

2021 ◽  
Vol 18 ◽  
Author(s):  
Elvan Wiyarta ◽  
Wismandari Wisnu

Background: Insulin has recently received special attention concerning its use in COVID-19 patients. Although controversial, insulin can be able to worsen the prognosis of COVID-19 patients with Type 2 Diabetes Mellitus (T2DM) through an inflammatory pathway. This uncertain aspect brings a new perspective related to insulin use in this pandemic era. Objective: We tried to collect and analyze various studies related to this issue to provide a complete picture of the prognosis of insulin use in COVID-19 patients with T2DM. Methods: We comprehensively searched PubMed, Cochrane CENTRAL, Embase, EBSCO CINAHL, MEDLINE, and grey literature databases for studies investigating the effect of insulin on COVID-19 outcomes, including mortality, hospitalization, disease progression, other prognostic surrogates. Records were screened against the eligibility criteria. Result: 2556 articles were retrieved and were screened. A total of 8 studies were included in the final analysis. There are no studies with solid evidence supporting the effect of insulin treatment on the worsening of the prognosis of COVID-19 patients with T2DM. Although several studies have shown that insulin is associated with a poor prognosis, most studies have not considered confounders. This certainly makes it challenging to analyze the effects of insulin independently. Conclusion: We propose that COVID-19 patients with T2DM continue to receive insulin, but with careful observation of the risk of disease progression.


Author(s):  
Ramalingaswamy Cheruku ◽  
Damodar Reddy Edla ◽  
Venkatanareshbabu Kuppili
Keyword(s):  

Author(s):  
Ramalingaswamy Cheruku ◽  
Damodar Reddy Edla ◽  
Venkatanareshbabu Kuppili
Keyword(s):  

Author(s):  
Ramalingaswamy Cheruku ◽  
Damodar Reddy Edla ◽  
Venkatanareshbabu Kuppili

2019 ◽  
Author(s):  
Sandra Reitmeier ◽  
Silke Kießling ◽  
Thomas Clavel ◽  
Markus List ◽  
Eduardo L. Almeida ◽  
...  

SummaryTo combat the epidemic increase in Type-2-Diabetes (T2D), risk factors need to be identified. Diet, lifestyle and the gut microbiome are among the most important factors affecting metabolic health. We demonstrate in 1,976 subjects of a prospective population cohort that specific gut microbiota members show diurnal oscillations in their relative abundance and we identified 13 taxa with disrupted rhythmicity in T2D. Prediction models based on this signature classified T2D with an area under the curve of 73%. BMI as microbiota-independent risk marker further improved diagnostic classification of T2D. The validity of this arrhythmic risk signature to predict T2D was confirmed in 699 KORA subjects five years after initial sampling. Shotgun metagenomic analysis linked 26 pathways associated with xenobiotic, amino acid, fatty acid, and taurine metabolism to the diurnal oscillation of gut bacteria. In summary, we determined a cohort-specific risk pattern of arrhythmic taxa which significantly contributes to the classification and prediction of T2D, highlighting the importance of circadian rhythmicity of the microbiome in targeting metabolic human diseases.


2018 ◽  
Vol 6 (1) ◽  
pp. e000604 ◽  
Author(s):  
Erin S LeBlanc ◽  
Ning X Smith ◽  
Gregory A Nichols ◽  
Michael J Allison ◽  
Gregory N Clarke

ObjectiveTo determine the possible association between insomnia and risk of type 2 diabetes mellitus (T2DM) in the naturalistic clinical setting.Research design and methodsWe conducted a retrospective cohort study to examine the risk of developing T2DM among patients with pre-diabetes with and without insomnia. Participants with pre-diabetes (identified by a physician or via two laboratory tests) between January 1, 2007 and December 31, 2015 and without sleep apnea were followed until December 31, 2016. Patients were determined to have T2DM when two of the following occurred within a 2-year window: physician-entered outpatient T2DM diagnosis (International Classification of Diseases [ICD]-9 250.00; ICD-10 E11), dispensing of an antihyperglycemia agent, and hemoglobin A1c (A1c) >6.5% (48 mmol/mol) or fasting plasma glucose (FPG) >125 mg/dL. One hospital inpatient stay with an associated T2DM diagnosis was also sufficient for classification of T2DM.ResultsOur cohort consisted of 81 233 persons with pre-diabetes, 24 146 (29.7%) of whom had insomnia at some point during the 4.3-year average observation period. After adjustment for traditional risk factors, those with insomnia were 28% more likely to develop T2DM than those without insomnia (HR 1.28; 95% CI 1.24 to 1.33). The estimate was essentially unchanged after adjusting for baseline A1c level (HR 1.32; 95% CI 1.25 to 1.40) or FPG (HR 1.28; 95% CI 1.23 to 1.33).ConclusionsInsomnia imparts an increased risk of T2DM comparable with that conferred by traditional risk factors (eg, overweight, non-white race, cardiovascular risk factors). This association could have clinical importance because it suggests a new potentially modifiable risk factor that could be targeted to prevent diabetes.


Diabetes Care ◽  
1999 ◽  
Vol 22 (6) ◽  
pp. 1011-1012 ◽  
Author(s):  
M. Fukui ◽  
N. Nakamura ◽  
M. Kondo

Diabetes Care ◽  
2005 ◽  
Vol 28 (7) ◽  
pp. 1798-1800 ◽  
Author(s):  
A. M. Wagner ◽  
A. Perez ◽  
J. L. Sanchez-Quesada ◽  
J. Ordonez-Llanos

Sign in / Sign up

Export Citation Format

Share Document